Name | Number of supported studies | Average coverage | |
---|---|---|---|
retinal cone cell | 4 studies | 38% ± 19% |
Insufficient scRNA-seq data for expression of P3H3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 3403.50 | 244 / 245 | 91% | 19.66 | 459 / 502 |
thymus | 100% | 2070.97 | 652 / 653 | 91% | 38.54 | 550 / 605 |
pancreas | 93% | 792.58 | 305 / 328 | 97% | 35.41 | 173 / 178 |
breast | 96% | 1773.96 | 442 / 459 | 91% | 30.04 | 1016 / 1118 |
lung | 99% | 1584.26 | 574 / 578 | 84% | 20.43 | 970 / 1155 |
bladder | 100% | 3145.33 | 21 / 21 | 79% | 21.23 | 399 / 504 |
adrenal gland | 95% | 1218.14 | 245 / 258 | 82% | 62.62 | 189 / 230 |
skin | 99% | 2404.18 | 1787 / 1809 | 75% | 23.71 | 355 / 472 |
uterus | 100% | 5646.88 | 170 / 170 | 71% | 32.19 | 327 / 459 |
stomach | 98% | 1347.32 | 353 / 359 | 71% | 10.84 | 203 / 286 |
ovary | 100% | 4766.41 | 180 / 180 | 69% | 13.78 | 298 / 430 |
intestine | 93% | 1746.05 | 903 / 966 | 70% | 12.88 | 369 / 527 |
brain | 80% | 1521.50 | 2124 / 2642 | 80% | 11.77 | 564 / 705 |
esophagus | 85% | 1513.00 | 1233 / 1445 | 58% | 9.34 | 107 / 183 |
kidney | 90% | 983.47 | 80 / 89 | 48% | 9.98 | 436 / 901 |
blood vessel | 100% | 3493.63 | 1333 / 1335 | 0% | 0 | 0 / 0 |
heart | 97% | 1610.79 | 837 / 861 | 0% | 0 | 0 / 0 |
adipose | 96% | 1458.00 | 1156 / 1204 | 0% | 0 | 0 / 0 |
spleen | 76% | 572.37 | 183 / 241 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 70% | 11.25 | 56 / 80 |
tonsil | 0% | 0 | 0 / 0 | 53% | 10.06 | 24 / 45 |
lymph node | 0% | 0 | 0 / 0 | 38% | 3.55 | 11 / 29 |
liver | 6% | 43.39 | 13 / 226 | 16% | 2.89 | 64 / 406 |
muscle | 8% | 50.09 | 61 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0.78 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0017185 | Biological process | peptidyl-lysine hydroxylation |
GO_0032964 | Biological process | collagen biosynthetic process |
GO_0032963 | Biological process | collagen metabolic process |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_1902494 | Cellular component | catalytic complex |
GO_0005506 | Molecular function | iron ion binding |
GO_0031418 | Molecular function | L-ascorbic acid binding |
GO_0019797 | Molecular function | procollagen-proline 3-dioxygenase activity |
Gene name | P3H3 |
Protein name | Prolyl 3-hydroxylase 3 (EC 1.14.11.7) (Leprecan-like protein 2) (Protein B) |
Synonyms | LEPREL2 |
Description | FUNCTION: Part of a complex composed of PLOD1, P3H3 and P3H4 that catalyzes hydroxylation of lysine residues in collagen alpha chains and is required for normal assembly and cross-linkling of collagen fibrils. Required for normal hydroxylation of lysine residues in type I collagen chains in skin, bone, tendon, aorta and cornea. Required for normal skin stability via its role in hydroxylation of lysine residues in collagen alpha chains and in collagen fibril assembly. Apparently not required for normal prolyl 3-hydroxylation on collagen chains, possibly because it functions redundantly with other prolyl 3-hydroxylases. . |
Accessions | Q8IVL6 ENST00000290510.10 [Q8IVL6-1] |